PubMed Health⌕ Search

PubMed · 10785987

Treating elevated lipids. Does it make a difference?

Abstract

BACKGROUND: There is now abundant evidence from clinical trials that treatment with lipid modifying therapy will decrease the risk of coronary heart disease (CHD). The decision to treat a patient, whether with advice on lifestyle modification or with drug therapy, needs to be based on consideration of costs versus benefits. OBJECTIVE: To assess the evidence from primary and secondary prevention studies for cardiovascular benefit of cholesterol lowering medication. DISCUSSION: Treating hypercholesterolaemia reduces the relative risk of major CHD events by about 30%. The greatest benefit of lipid lowering treatment is in the high risk group. This group shows the greatest reduction in absolute risk and therefore a 'smaller number to treat' to prevent one major CHD event. In the moderate risk group three times as many individuals require treatment to prevent one major CHD event. However, this corresponds to the benefit in primary prevention of stroke by treating mild-moderate hypertension in middle aged men.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J Best, D O'Neal. 2000. Treating elevated lipids. Does it make a difference?. https://pubmed.health/record/pubmed%3A10785987/treating-elevated-lipids-does-it-make-a-difference

Citations retain the original authors and DOI and include this site’s record URL. If this discovery service contributed to your research, you can also cite PubMed Health by Indiciae: BibTeX · RIS.

KEEP EXPLORING

Related citations

Update on PPAR agonists: the clinical significance of FIELD and PROACTIVE.

The peroxisome proliferator-activated receptor (PPAR) family of genes plays a major role in metabolic regulation. Unfortunately, the results of two recent, large event trials of PPAR agonists have been mixed. High rates of crossover to statin use confound the interpretation of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial, which found a less than expected reduction in coronary and stroke events with fenofibrate. Of concern, nonsignificant increases in coronary and sudden deaths, thrombotic events, and pancreatitis occurred in the fenofibrate group. The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROACTIVE) also found a reduction in coronary and stroke events with pioglitazone compared with placebo in a population with diabetes and cardiovascular disease, but this benefit was counterbalanced by an increase in congestive heart failure as well as symptomatic edema. Further research is needed to determine the role of PPAR agonists in the prevention of cardiovascular disease.

Coronary Disease↗

Depressive symptoms and sex affect completion rates and clinical outcomes in cardiac rehabilitation.

Symptoms of depression are often seen in patients with coronary heart disease. Symptoms appear more commonly in women and are negatively associated with measures of cardiovascular health. Using multiple logistic regression analyses, the authors evaluated the independent effects of depression (as measured by the Beck Depression Inventory [BDI-II]) and sex on cardiac rehabilitation (CR) completion. In addition, in those who completed CR, the authors evaluated whether depressive symptoms and sex affected clinical outcomes. Women as well as participants with enrollment BDI-II scores > or =14 had significantly higher rates of CR noncompletion. Patients with BDI-II scores > or =14 who completed CR achieved significant improvements in lipid profile, body mass index, and exercise capacity regardless of sex. Women and individuals with BDI-II scores > or =14 are at risk for CR noncompletion and should be encouraged to complete CR, because cardiovascular benefits comparable to those seen in men and individuals with low BDI-II scores were achieved when these patients completed the CR program.

Coronary Disease↗